objective interindividual clinical response leukotriene modifiers highly variable efficacious inhaled corticosteroids treating asthma genetic variability biosynthetic receptor pathway gene loci influence production subsequent response leukotriene modifiers methods using data clinical trials duration analyses performed NUMBER patients randomized montelukast associations polymorphisms NUMBER candidate genes alox5 alox5ap ltc4s cysltr1 cysltr2 pla2g4a cyp2c9 cyp3a4 adrb2 nr3c1 response montelukast modeled using change morning peak expiratory flow forced expiratory volume NUMBER s fev1 define response phenotype results sample NUMBER markers NUMBER candidate genes statistically associated response montelukast estimated proportion false discoveries NUMBER strongest statistical evidence clinically relevant pharmacogenetic effects peak expiratory flow identified cysltr2 rs91227 rs912278 p002 p002 respectively alox5 rs4987105 rs4986832 p001 p001 respectively patients variant genotypes roughly patients improvement peak expiratory flow contrast majority patients alleles marginal improvement conclusions overall mean response montelukast skewed response phenotype small subset NUMBER asthma patients cysltr2 alox5 polymorphisms predispose minority individuals excessive concentrations yielding distinct asthma phenotype likely respond leukotriene modifier pharmacotherapy findings require replication establish validity clinical utility NUMBER lipoxygenase cysteinyl leukotriene NUMBER week post hoc NUMBER NUMBER NUMBER NUMBER wild type NUMBER NUMBER cysteinyl leukotriene